Early diabetic neuropathy: Triggers and mechanisms

World Journal of Gastroenterology

Volumn 13, Issue 2, 2007, Pages 175-191

  Dobretsov, Maxim ^a   Romanovsky, Dmitry ^a   Stimers, Joseph R ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Diabetes; Hyperglycemia; Impaired glucose tolerance; Insulin resistance; Insulinopenia; Neuropathy; Pre diabetes

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; INSULIN RECEPTOR; SOMATOMEDIN;

DIABETIC NEUROPATHY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; LOW DRUG DOSE; NERVE CONDUCTION; NEUROMODULATION; NEUROPATHIC PAIN; NONHUMAN; OXIDATIVE STRESS; PARESTHESIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; PREVALENCE; REVIEW; ZUCKER DIABETIC FATTY RAT;

EID: 33846940322     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i2.175     Document Type: Review

References (189)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29 Suppl 1: S43-S48
2. Diabetes in America. Bethesda MR: National Diabetes Data Group, NIH, 1995: 1-733
3. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197
4. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006; 29 Suppl 1: S4-S42
5. Stryer L. Biochemistry. New York: W.H. Freeman and Company, 1988: 1-1089
6. Zierler K. Whole body glucose metabolism. Am J Physiol 1999; 276: E409-13426
7. Kono T, Barham FW. The relationship between the insulin-binding capacity of fat cells and the cellular response to insulin. Studies with intact and trypsin-treated fat cells. J Biol Chem 1971; 246: 6210-6216
8. Gliemann J, Gammeltoft S, Vinten J. Time course of insulin-receptor binding and insulin-induced lipogenesis in isolated rat fat cells. J Biol Chem 1975; 250: 3368-3374
9. Kahn BB, Rossetti L. Type 2 diabetes - who is conducting the orchestra? Nat Genet 1998; 20: 223-225
10. Olefsky JM. Insensitivity of large rat adipocytes to the antilipolytic effects of insulin. J Lipid Res 1977; 18: 459-464
11. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986; 314: 1360-1368
12. Kobayashi T, Kamata K. Effect of insulin treatment on smooth muscle contractility and endothelium-dependent relaxation in rat aortae from established STZ-induced diabetes. Br J Pharmacol 1999; 127: 835-842
13. Burcelin R, Eddouks M, Kande J, Assan R, Girard J. Evidence that GLUT-2 mRNA and protein concentrations are decreased by hyperinsulinaemia and increased by hyperglycaemia in liver of diabetic rats. Biochem J 1992; 288 (Pt 2): 675-679
14. Rossetti L, Giaccari A. Relative contribution of glycogen synthesis and glycolysis to insulin-mediated glucose uptake. A dose-response euglycemic clamp study in normal and diabetic rats. J Clin Invest 1990; 85: 1785-1792
15. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987; 80: 1037-1044
16. Russell JW, Golovoy D, Vincent AM, Mahendru P, Olzmann JA, Mentzer A, Feldman EL. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 2002 16: 1738-1748
17. Lin CY, Higginbotham DA, Judd RL, White BD. Central leptin increases insulin sensitivity in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2002; 282: E1084-E1091
18. Patlak M. New weapons to combat an ancient disease: treating diabetes. FASEB J 2002; 16: 1853
19. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza, F, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167
20. Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, Kochba I, Rudich A. Normal fasting plasm glucose levels and type 2 diabetes in young men. N Engl J Med 2005; 353: 1454-1462
21. Godsland IF, Jeffs JA, Johnston DG. Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 2004; 47: 1157-1166
22. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006; 81: S3-11
23. Vinik AI, Newlon P, Milicevic Z, McNitt P, Stansberry KB. Diabetic neuropathies: an overview of clinical aspects. In: LeRoith D, Taylor SI, Olefsky JM. Diabetes Mellitus. Philadelphia, New-York: Lippincott-Raven Publishers, 1996: 737-751
24. Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004; 88: 947-999, xi
25. Polydefkis M, Griffin JW, McArthur J. New insights into diabetic polyneuropathy. JAMA 2003; 290: 1371-1376
26. Horowitz SH. Diabetic neuropathy. Clin Orthop Relat Res 1993; 296: 78-85
27. Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy - a continuing enigma. Diabetes Metab Res Rev 2000; 16: 408-433
28. Bastyr EJ 3rd, Price KL, Bril V. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther 2005; 27: 1278-1294
29. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988; 11: 21-32
30. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman F. Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962
31. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997; 46 Suppl 2: S54-S57
32. Young RJ, Zhou YQ, Rodriguez E, Prescott RJ, Ewing DJ, Clarke BF. Variable relationship between peripheral somatic and autonomic neuropathy in patients with different syndromes of diabetic polyneuropathy. Diabetes 1986; 35: 192-197
33. Young RJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology. Diabetes Care 1988; 11: 34-40
34. Maser RE, Nielsen VK, Bass EB, Manjoo Q, Dorman JS, Kelsey SP, Becker DJ, Orchard TJ. Measuring diabetic neuropathy. Assessment and comparison of clinical examination and quantitative sensory testing. Diabetes Care 1989; 12: 270-275
35. Navarro X, Kennedy WR, Fries TJ. Small nerve fiber dysfunction in diabetic neuropathy. Muscle Nerve 1989; 12: 498-507
36. Ellenberg M. Diabetic neuropathy: clinical aspects. Metabolism 1976; 25: 1627-1655
37. Boulton AJ. Management of diabetic peripheral neuropathy. Clinical Diabetes 2005; 23: 9-15
38. Belgrade MJ, Cole BE, McCarberg BH, McLean MJ. Diabetic peripheral neuropathic pain: case studies. Mayo Clin Proc 2006; 81: S26-S32
39. Pfeifer MA, Ross DR, Schrage JP, Gelber DA, Schumer MP, Crain GM, Markwell SJ, Jung S. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care 1993; 16: 1103-1115
40. Benbow SJ, MacFarlane IA. Painful diabetic neuropathy. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13: 295-308
41. Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol and Exp Neurol 1996; 55: 1181-1193
42. Thomas PK. Diabetic neuropathy: mechanisnis and future treatment options. J Neurol Neurosurg Psychiatry 1999; 67: 277-279
43. Zochodne DW. Neurotrophins and other growth factors in diabetic neuropathy. Semin Neurol 1996; 16: 153-161
44. Liuzzi FJ, Bufton SM, Vinik AI. Streptozotocin-induced diabetes mellitus causes changes in primary sensory neuronal cytoskeletal mRNA levels that mimic those caused by axotomy. Exp Neurol 1998; 154: 381-388
45. Koltzenburg M, Scadding J. Neuropathic pain. Curr Opin Neurol 2001; 14: 641-647
46. Torebjork HE, Lundberg LE, Lamotte RH. Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperalgesia. in humans. J Physiol 1992; 448: 765-780
47. Ochoa JL, Torebjork HE. Paraesthesiae from ectopic impulse generation in human sensory nerves. Brain 1980; 103: 835-853
48. Mogyoros I, Bostock H, Burke D. Mechanisms of paresthesias arising from healthy axons. Muscle Nerve 2000; 23: 310-320
49. Wallace VC, Cottrell DF, Brophy PJ, Fleetwood-Walker SM. Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids. J Neurosci 2003; 23: 3221-3233
50. Sima AA, Nathaniel V, Bril V, McEwen TA, Greene DA. Histopathological heterogeneity of neuropathy in insulin - dependent and non-insulin-dependent diabetes, and demonstration of axo- glial dysjunction in human diabetic neuropathy. J Clin Invest 1988; 81: 349-364
51. Dyck PJ, Lambert EH, O'Brien PC. Pain in peripheral neuropathy related to rate and land of fiber degeneration. Neurology 1976; 26: 466-471
52. Bonica JJ. The Managment of Pain. In: Loeser JD, Chapman CR, Fordyce WE. Philadelphia, London: Lea & Febiger, 1990: 1-958
53. Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multi-center placebo- controlled double-blind parallel group study. Diabetes Care 2001; 24: 1776-1782
54. Brown MJ, Martin JR, Asbury AK. Painful diabetic neuropathy. A morphornetric study. Arch Neurol 1976; 33: 164-171
55. Britland ST, Young RJ, Sharma AK, Clarke BF. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Diabetes 1990; 39: 898-908
56. Sima AA. Peripheral neuropathy in the spontaneously diabetic BB-Wistar-rat. An ultrastructural study. Acta Neuropathol (Berl) 1980; 51: 223-227
57. Waxman SG. Pathophysiology of nerve conduction: relation to diabetic neuropathy. Ann Intern Med 1980; 92: 297-301
58. Johnson PC, Doll SC, Cromey DW. Pathogenesis of diabetic neuropathy. Ann Neurol 1986; 19: 450-457
59. Dyck PJ, Karnes JL, O'Brien P, Okazaki H, Lais A, Engelstad J. The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia. Ann Neurol 1986; 19: 440-449
60. Dyck PJ, Lais A, Karnes JL, O'Brien P, Rizza R. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986; 19: 425-439
61. Dyck PJ, Gutrecht JA, Bastron JA, Karnes WE, Dale AJ. Histologic and teased-fiber measurements of sural nerve in disorders of lower motor and primary sensory neurons. Mayo Clin Proc 1968; 43: 81-123
62. Malik RA. The pathology of human diabetic neuropathy. Diabetes 1997; 46 Suppl 2: S50-S53
63. Nathan DM. The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Ann Intern Med 1996; 124: 86-89
64. Vinik AI. Advances in diabetes for the millennium: new treatments for diabetic neuropathies. MedGenMed 2004; 6: 13
65. Skyler JS. Effec of glycemic control on diabetes complications and on the prevention of diabetes. Clinical Diabetes 2004; 22: 162-166
66. Chronic Complications in Diabetes. Ed: Sima. AA. Animal Models and Chronic Complications. Amsterdam: Harwood Academic Publishers, 2000: 1-277
67. Lasker RD. The diabetes control and complications trial. Implications for policy and practice. N Engl J Med 1993; 329: 1035-1036
68. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986
69. Bode BW, Schwartz S, Stubbs HA, Block JE. Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care 2005; 28: 2361-2366
70. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001; 24: 1448-1453
71. Novella SP, Inzucchi SE, Goldstein JM. The frequency of undiagnosed diabebes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve 2001; 24: 1229-1231
72. Animal Models of Diabetes. Eds: Sima AA, Shaffir E. A Primer. Amsterdam: Harwood Acaden-dc Publishers, 2001: 1-364
73. Moore SA, Peterson RG, Felten DL, O'Connor BL. A quantitative comparison of motor and sensory conduction velocities in short- and long-term streptozotocin- and alloxan-diabetic rats. J Neurol Sci 1980; 48: 133-152
74. Weis J, Dimpfel W, Schroder JM. Nerve conduction changes and fine structural alterations of extra- and intrafusal muscle and nerve fibers in streptozotocin diabetic rats. Muscle Nerve 1995; 18: 175-184
75. Stevens MJ, Zhang W, Li F, Sima AA. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab 2004; 287: E497-E505
76. Zochodne DW, Ho LT, Allison JA. Dorsal root ganglia micro-environment of female BB Wistar diabetic rats with mild neuropathy. J Neurol Sci 1994; 127: 36-42
77. Ferreira LD, Huey PU, Pufford BE, Ishii DN, Eckel RH. Sciatic nerve lipoprotein lipase is reduced in streptozotocin-induced diabetes and corrected by insulin. Endocrinology 2002; 143: 1213-1217
78. Coppey LJ, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Int J Exp Diabetes Res 2000; 1: 131-143
79. Qiang X, Satoh J, Sagara M, Fukuzawa M, Masuda T, Sakata Y, Muto G, Muto Y, Takahashi K, Toyota T. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia 1998; 41: 1321-1326
80. Sima AA, Brismar T. Reversible diabetic nerve dysfunction: structural correlates to electrophysiological abnormalities. Ann Neurol 1985; 18: 21-29
81. Sima AA, Lattimer SA, Yagihashi S, Greene DA. Axo-glial dysjunction. J Clin Invest 1986; 77: 474-484
82. Greene DA, Chakrabarti S, Lattimer SA, Sima AA. Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic bio-breeding rat. Reversal by insulin replacement, an aldose reductase inhibitor, and myo-inositol. J Clin Invest 1987; 79: 1479-1485
83. Shimoshige Y, Ikuma K, Yamamoto T, Takakura S, Kawamura I, Seki J, Mutoh S, Goto T. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats. Metabolism 2000; 49: 1395-1399
84. Romanovsky D, Hastings SL, Stimers JR, Dobretsov M. Relevance of hyperglycemia to early mechanical hyperalgesia in streptozotocin-induced diabetes. J Peripher Nerv Syst 2004; 9: 62-69
85. Chen SR, Pan HL. Hypersensitivity of spinothalamic tract neurons associated with diabetic neuropathic pain in rats. J Neurophysiol 2002; 87: 2726-2733
86. Zhuang HX, Wuarin L, Fei ZJ, Ishii DN. Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with non-insulin-dependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy. J Pharmacol Exp Ther 1997; 283: 366-374
87. Piercy V, Banner SE, Bhattacharyya A, Parsons AA, Sanger GJ, Smith SA, Bingham S. Thermal, but not mechanical, nociceptive behavior is altered in the Zucker Diabetic Fatty rat and is independent of glycemic status. J Diabetes Complications 1999; 13: 163-169
88. Schmidt RE, Dorsey DA, Beaudet LN, Parvin CA, Zhang W, Sima AA. Experimental rat models of types 1 and 2 diabetes differ in sympathetic neuroaxonal dystrophy. J Neuropathol Exp Neurol 2004; 63: 450-460
89. Brussee V, Cunningham FA, Zochodne DW. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 2004; 53: 1824-1830
90. Schmeichel AM, Schmelzer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003; 52: 165-171
91. Cameron NE, Cotter MA, Low PA. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 1991; 261: E1-E8
92. Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler H, Low PA. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160-1167
93. Cameron NE, Cotter MA, Jack AM, Basso MD, Hohman TC. Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999; 42: 1120-1130
94. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001; 18: 945-959
95. Hamdy O, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Caselli A, Caballero AE, Economides PA, Veves A, Horton ES. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003; 26: 2119-2125
96. Huvers FC, De Leeuw PW, Houben AJ, De Haan CH, Hamulyak K, Schouten H, Wolffenbuttel BH, Schaper NC. Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes 1999; 48: 1300-1307
97. Khan F, Elhadd TA, Greene SA, Belch JJ. Impaired skin microvascular function in children, adolescents, and young adults with type 1 diabetes. Diabetes Care 2000; 23: 215-220
98. Caballero AE, Arora. S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, Horton ES, Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48: 1856-1862
99. Theriault M, Dort J, Sutherland G, Zochodne DW. Local human sural nerve blood flow in diabetic and other polyneuropathies. Brain 1997; 120 (Pt 7): 1131-1138
100. Dobretsov M, Hastings SL, Stimers JR, Zhang J-M. Mechanical hyperalgesia in rats with chronic perfusion of lumbar dorsal root ganglion with hyperglycemic solution. J Neurosci Methods 2001; 110: 9-15
101. Dobretsov M, Hastings SL, Romanovsky D, Stimers; JR, Zhang JM. Mechanical hyperalgesia in rat models of systemic and local hyperglycemia. Brain Res 2003; 960: 174-183
102. King RH. The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol Pathol 2001; 54: 400-408
103. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 2005; 26: 380-392
104. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 1998; 50: 21-33
105. Reusch JE. Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose? J Clin Invest 2003; 112: 986-988
106. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625
107. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension 1998; 31: 1047-1060
108. Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal 2005; 7: 1568-1580
109. Wang Y, Schmeichel AM, Iida H, Schmelzer JD, Low PA. Ischemia-reperfusion injury causes oxidative stress and apoptosis of Schwann cell in acute and chronic experimental diabetic neuropathy. Antioxid Redox Signal 2005; 7: 1513-1520
110. Chait A, Brunzell JD. Diabetes, lipids, and atherosclerosis. In: LeRoith D, Taylor SI, Olefsky JM. Diabetes Mellitus. Philadelphia, New York: Lippincott-Raven Publishers, 1996: 772-777
111. Obrosova IG. Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. Antioxid Redox Signal 2005; 7: 1543-1552
112. Kellogg AP, Pop-Busui R. Peripheral nerve dysfunction in experimental diabetes is mediated by cyclooxygenase-2 and oxidative stress. Antioxid Redox Signal 2005; 7: 1521-1529
113. Greene DA, Stevens MJ, Obrosova I, Feldman EL. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur J Pharmacol 1999; 375: 217-223
114. Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest 2003; 111: 431-433
115. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816-823
116. Kishi Y, Schmelzer JD, Yao JK, Zollman PJ, Nickander KK, Tritschler HJ, Low PA. Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes 1999; 48: 2045-2051
117. Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003; 26: 770-776
118. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003; 17: 24-38
119. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005; 4: 5-25
120. Petersen M, LaMotte RH. Relationships between capsaicin sensitivity of mammalian sensory neurons, cell size and type of voltage gated Ca-currents. Brain Res 1991; 561: 20-26
121. Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 2002; 16: 123-125
122. Young RJ, Ewing DJ, Clarke BF. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 1983; 32: 938-942
123. Martyn CN, Reid W, Young RJ, Ewing DJ, Clarke BF. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function. Diabetes 1987; 36: 987-990
124. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004; 27: 1458-1483
125. Singleton JR, Smith AG, Russell J, Feldman EL. Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy. Curr Treat Options Neurol 2005; 7: 33-42
126. Russell JW, Feldman EL. Impaired glucose tolerance - does it cause neuropathy? Muscle Nerve 2001; 24: 1109-1112
127. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001; 24: 1225-1228
128. Pittenger GL, Mehrabyan A, Simmons K, Rice A, Dublin C, Barlow P, Vinik AI. Small fiber neuropathy is associated with the metabolic syndrome. Metabolic Syndrome and Related Disorders 2005; 3: 113-121
129. Sumner CJ, Sheth S, Griffin JW, Comblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108-111
130. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687
131. de Neeling JN, Beks PJ, Bertelsmann FW, Heine RJ, Bouter LM. Peripheral somatic nerve function in relation to glucose tolerance in an elderly Caucasian population: the Hoorn study. Diabet Med 1996; 13: 960-966
132. Morley GK, Mooradian AD, Levine AS, Morley JE. Mechanism of pain in diabetic peripheral neuropathy. Effect of glucose on pain perception in humans. Am J Med 1984; 77: 79-82
133. Thye-Ronn P, Sindrup SH, Arendt-Nielsen L, Brennum J, Hother-Nielsen O, Beck-Nielsen H. Effect of short-term hyperglycemia per se on nociceptive and non-nociceptive thresholds. Pain 1994; 56: 43-49
134. Chan AW, MacFarlane IA, Bowsher D. Short term fluctuations in blood glucose concentrations do not alter pain perception in diabetic-patients with and without painful peripheral neuropathy. Diabetes Res 1990; 14: 15-19
135. Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 2002; 19: 870-873
136. Huang TJ, Price SA, Chilton L, Calcutt NA, Tomlinson DR, Verkhratsky A, Fernyhough P. Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes 2003; 52: 2129-2136
137. Maneuf YP, Blake R, Andrews NA, McKnight AT. Reduction by gabapentin of K+-evoked release of [3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat. Br J Pharmacol 2004; 141: 574-579
138. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 1996; 68: 293-299
139. Calcutt NA, Freshwater JD, Mizisin AP. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 2004; 47: 718-724
140. Roane DS, Porter JR. Nociception and opioid-induced analgesia in lean (Fa/-) and obese (fa/fa) Zucker rats. Physiol Behav 1986; 38: 215-218
141. Oltman CL, Coppey LJ, Gellett JS, Davidson EP, Lund DD, Yorek MA. Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats. Am J Physiol Endocrinol Metab 2005; 289: E113-E122
142. Ishii DN. Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Brain Res Rev 1995; 20: 47-67
143. Sugimoto K, Murakawa Y, Zhang W, Xu G, Sima AA. Insulin receptor in rat peripheral nerve: its localization and alternatively spliced isoforms. Diabetes Metab Res Rev 2000; 16: 354-363
144. Sugimoto K, Murakawa Y, Sima AA. Expression and localization of insulin receptor in rat dorsal root ganglion and spinal cord. J Peripher Nerv Syst 2002; 7: 44-53
145. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R. Insulin receptor isoform. A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999; 19: 3278-3288
146. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340-344
147. Singhal A, Cheng C, Sun H, Zochodne DW. Near nerve local insulin prevents conduction slowing in experimental diabetes. Brain Res 1997; 763: 209-214
148. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 89-94
149. Delaney CA, Mouser JV, Westerman RA. Insulin sensitivity and sensory nerve function in non-diabetic human subjects. Neurosci Lett 1994; 180: 277-280
150. Jacob S, Streeper RS, Fogt DL, Hokama JY, Tritschler HJ, Dietze GJ, Henriksen EJ. The antioxidant alpha-lipoic acid enhances insulin-stimulated glucose metabolism in insulin-resistant rat skeletal muscle. Diabetes 1996; 45: 1024-1029
151. Broca C, Breil V, Cruciani-Guglielmacci C, Manteghetti M, Rouault C, Derouet M, Rizkalla S, Pau B, Petit P, Ribes G, Ktorza A, Gross R, Reach G, Taouis M. Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat. Am J Physiol Endocrinol Metab 2004; 287: E463-E471
152. Wong V, Stavar L, Szeto L, Uffelman K, Wang CH, Fantus IG, Lewis GF. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 2006; 184: 348-355
153. Freychet P. Insulin receptors and insulin actions in the nervous system. Diabetes Metab Res Rev 2000; 16: 390-392
154. Kihara M, Zollman PJ, Smithson IL, Lagerlund TD, Low PA. Hypoxic effect of exogenous insulin on normal and diabetic peripheral nerve. Am J Physiol 1994; 266: E980-E985
155. Dandona P, Mohanty P, Chaudhuri A, Garg R, Aljada A. Insulin infusion in acute illness. J Clin Invest 2003; 115: 2069-2072
156. Nedrebo T, Karlsen TV, Salvesen GS, Reed RK. A novel function of insulin in rat dermis. J Physiol 2004; 559: 583-591
157. Jeschke MG, Einspanier R, Klein D, Jauch KW. Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Med 2002; 8: 443-450
158. Davel AP, Rossoni LV, Vassallo DV. Effects of ouabain on the pressor response to phenylephrine and on the sodium pump activity in diabetic rats. Eur J Pharmacol 2000; 406: 419-427
159. Sweeney G, Klip A. Regulation of the Na+/K+-ATPase by insulin: why and how? Mol Cell Biochem 1998; 182: 121-133
160. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172-1179
161. Ranke MB. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab 2005; 16: 190-197
162. Recio-Pinto E, Rechler MM, Ishii DN. Effects of insulin, insulin-like growth factor-II, and nerve growth factor on neurite formation and survival in cultured sympathetic and sensory neurons. J Neurosci 1986; 6: 1211-1219
163. Mill JF, Chao MV, Ishii DN. Insulin, insulin-like growth factor II, and nerve growth factor effects on tubulin mRNA levels and neurite formation. Proc Natl Acad Sci U S A 1985; 82: 7126-7130
164. Near SL, Whalen LR, Miller JA, Ishii DN. Insulin-like growth factor II stimulates motor nerve regeneration. Proc Natl Acad Sci U S A 1992; 89: 11716-11720
165. Dupont J, Khan J, Qu BH, Metzler P, Hehnan L, LeRoith D. Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology 2001; 142: 4969-4975
166. Meier C, Parmantier E, Brennan A, Mirsky R, Jessen KR. Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. J Neurosci 1999; 19: 3847-3859
167. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P, Le Bouc Y. IGF-l receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003; 421: 182-187
168. Rajkumar K, Krsek M, Dheen ST, Murphy LJ. Impaired glucose homeostasis in insulin-like growth factor binding protein-1 transgenic mice. J Clin Invest 1996; 98: 1818-1825
169. Karagiannis SN, King RH, Thomas PK. Colocalisation of insulin and IGF-1 receptors in cultured rat sensory and sympathetic ganglion cells. J Anat 1997; 191 (Pt 3): 431-440
170. Craner MJ, Klein JP, Black JA, Waxman SG. Preferential expression of IGF-I in small DRG neurons and down-regulation following injury. Neuroreport 2002; 13: 1649-1652
171. Cheng HL, Randolph A, Yee D, Delafontaine P, Tennekoon G, Feldman EL. Characterization of insulin-like growth factor-I and its receptor and binding proteins in transected nerves and cultured Schwann cells. J Neurochem 1996; 66: 525-536
172. Jonas HA, Harrison LC. The human placenta contains two distinct binding and immunoreactive species of insulin-like growth factor-I receptors. J Biol Chem 1985; 260: 2288-2294
173. Moxham CP, Duronio V, Jacobs S. Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodirners. J Biol Chem 1989; 264: 13238-13244
174. Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, Skarulis M. Clinical uses of insulin-like growth factor I. Ann Intern Med 1994; 120: 593-601
175. Saukkonen T, Amin R, Williams RM, Fox C, Yuen KC, White MA, Umpleby AM, Acerini CL, Dunger DB. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 2004; 89: 4634-4641
176. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 2000; 85: 1518-1524
177. Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha PM, Jr. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM
178. Cusi K, DeFronzo R. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab 2000; 85: 3077-3084
179. Schmidt RE, Dorsey DA, Beaudet LN, Peterson RG. Analysis of the Zucker Diabetic Fatty (ZDF) type 2 diabetic rat model suggests a neurotrophic role for insulin/IGF-I in diabetic autonomic neuropathy. Am J Pathol 2003; 163: 21-28
180. Busiguina S, Fernandez AM, Barrios V, Clark R, Tolbert DL, Berciano J, Torres-Aleman I. Neurodegeneration is associated to changes in serum insulin-like growth factors. Neurobiol Dis 2000; 7: 657-665
181. Chen HS, Shan YX, Yang TL, Lin HD, Chen JW, Lin SJ, Wang PH. Insulin deficiency downregulated heat shock protein 60 and IGF-1 receptor signaling in diabetic myocardium. Diabetes 2005; 54: 175-181
182. Zhuang HX, Wuarin L, Fei ZJ, Ishii DN. Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with non-insulin-dependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy. J Pharmacol Exp Ther 1997; 283: 366-374
183. Jacob RJ, Sherwin RS, Greenawalt K, Shulman GI. Simultaneous insulinlike growth factor I and insulin resistance in obese Zucker rats. Diabetes 1992; 41: 691-697
184. Sima AA. Diabetic neuropathy in type 1 and type 2 diabetes and the effects of C-peptide. J Neurol Sci 2004; 220: 133-136
185. Sima AA, Zhang W, Grunberger G. Type 1 diabetic neuropathy and C-peptide. Exp Diabesity Res 2004; 5: 65-77
186. Kamiya H, Zhang W, Sima AA. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol 2004; 56: 827-835
187. Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindstrom P, Wahren J. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes 2003; 52: 536-541
188. Forst T, Kunt T, Pohhmann T, Goitom K, Engelbach M, Beyer J, Pfutzner A. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest 1998; 101: 2036-2041
189. Rola R, Szulczyk P. Quantitative differences between kinetic properties of Na(+) currents in postganglionic sympathetic neurones projecting to muscular and cutaneous effectors. Brain Res 2000; 857: 327-336